NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,537.81 +223.95 (+1.22%) CRUDE OIL
79.40 +0.41 (+0.52%) GOLD FUTURES
2,343.40 +21.10 (+0.91%) DOW
39,375.95 +319.56 (+0.82%) Bitcoin GBP
49,652.57 -244.94 (-0.49%)
Tyra Biosciences, Inc. (TYRA)
| Previous close | 18.03 |
| Open | 18.14 |
| Bid | 17.80 x 100 |
| Ask | 18.02 x 100 |
| Day's range | 17.89 - 18.41 |
| 52-week range | 10.38 - 20.67 |
| Volume | |
| Avg. volume | 132,557 |
| Market cap | 940.666M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.62 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.60 |
PR NewswireTyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced changes to its Board of Directors with the appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D. The changes are effective immediately.
- GuruFocus.com
Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress
Recent Financial Highlights Indicate Strong Cash Position and Advancements in Clinical Studies
- PR Newswire
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent corporate progress.
